Experiencia clínica con los cannabinoides en la terapia de la espasticidad en la esclerosis múltiple

Fernández, L. Lorente; Monte-Boquet, Emilio; Pérez‐Miralles, Francisco; Gómez, Inés; Roig, M. Escutia; Blasco, Inma; Andres, Jennifer; Casanova-Estruch, B

doi:10.1016/j.nrl.2013.06.014

Cited by 15 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first section assesses knowledge of medical marijuana, including therapeutic uses and adverse effects. Only uses [3] and adverse effects [10][11][12][13][14][15][16][17] of cannabinoid-based medicines authorized in European Union countries were included. The second section measures students' attitudes and opinions regarding medical and recreational use of marijuana and evaluates their confidence levels regarding efficacy, safety and drug interactions of medical marijuana using 23 questions with a five-point Likert scale for each (1 = strongly disagree to 5 = strongly agree).…”

Section: Data Collectionmentioning

confidence: 99%

See 1 more Smart Citation

Nursing Students’ Knowledge and Attitudes Regarding Medical Marijuana: A Descriptive Cross-Sectional Study

Pereira¹,

Núñez-Iglesias

Domínguez-Martís³

et al. 2020

IJERPH

View full text Add to dashboard Cite

Marijuana use for medical purposes dates back to ancient times. Despite its high therapeutic potential, its adverse effects have raised important legal restrictions. However, this situation in Spain may soon undergo significant changes, without anyone so far having studied the knowledge and/or the level of acceptance of medical marijuana by future healthcare professionals. The aim of the present study was to determine nursing students’ knowledge of and attitudes towards medical marijuana. A cross-sectional design was used. A total of 578 nursing students from the University of Santiago de Compostela (Spain), ≥18 years old and of both sexes, were invited to complete the Spanish version of the questionnaire “Medical Marijuana” between January and May 2019. A total of 364 students decided to participate in the study. More than 75% of the students agreed with the legalization of medical marijuana, although their knowledge and confidence levels regarding efficacy, safety and drug interactions of medical marijuana were low. Nursing students showed a clear lack of knowledge about medical marijuana and thus, in light of possible regulatory changes, it would be necessary to strengthen the training of nurses with respect to medical marijuana in order to make responsible use of it.

show abstract

Section: Data Collectionmentioning

confidence: 99%

“…Sativex, Cesamet, Marinol, etc.) to treat a variety of conditions such as spasticity, chronic pain and others [3,[6][7][8][9], despite the potential for side effects [10][11][12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Nursing Students’ Knowledge and Attitudes Regarding Medical Marijuana: A Descriptive Cross-Sectional Study

Pereira¹,

Núñez-Iglesias

Domínguez-Martís³

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…CBD has long lasting effects (up to 80 days) and has been used for the treatment of inflammatory pain and multiple sclerosis (MS) in mouse models (11). In humans CBD treatment safely and effectively reduces symptoms of pain and spasticity in MS patients (12). Additionally, both CBD and Abn-CBD mediate a potentially protective role in diabetes (13, 14).…”

Section: Introductionmentioning

confidence: 99%

Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity

Simcocks

Jenkin

O’Keefe

et al. 2019

Endocrine Connections

View full text Add to dashboard Cite

Atypical cannabinoid compounds O-1602 and O-1918 are ligands for the putative cannabinoid receptors G protein-coupled receptor 55 and G protein-coupled receptor 18. The role of O-1602 and O-1918 in attenuating obesity and obesity-related pathologies is unknown. Therefore, we aimed to determine the role that either compound had on body weight and body composition, renal and hepatic function in diet-induced obesity. Male Sprague–Dawley rats were fed a high-fat diet (40% digestible energy from lipids) or a standard chow diet for 10 weeks. In a separate cohort, male Sprague–Dawley rats were fed a high-fat diet for 9 weeks and then injected daily with 5 mg/kg O-1602, 1 mg/kg O-1918 or vehicle (0.9% saline/0.75% Tween 80) for a further 6 weeks. Our data demonstrated that high-fat feeding upregulates whole kidney G protein receptor 55 expression. In diet-induced obesity, we also demonstrated O-1602 reduces body weight, body fat and improves albuminuria. Despite this, treatment with O-1602 resulted in gross morphological changes in the liver and kidney. Treatment with O-1918 improved albuminuria, but did not alter body weight or fat composition. In addition, treatment with O-1918 also upregulated circulation of pro-inflammatory cytokines including IL-1α, IL-2, IL-17α, IL-18 and RANTES as well as plasma AST. Thus O-1602 and O-1918 appear not to be suitable treatments for obesity and related comorbidities, due to their effects on organ morphology and pro-inflammatory signaling in obesity.

show abstract

“…Three main active principles derived from cannabis formulate these drugs: dronabinol (Marinol ® ), a synthetic isomer of Δ 9 -THC, nabilone (Cesamet ® ), a synthetic analogue of Δ 9 -THC and nabiximols (Sativex ® ), a 1:1 mix of Δ 9 -THC and CBD [380]. Sativex ® consists of an oral spray approved in some European countries and Canada for the treatment of spasticity and pain relief in MS patients, with mild-to-moderate side effects that occur scarcely in patients [379,380,406,407,408,409,410,411,412,413,414,415,416]. Nevertheless, no trial has shown a slower disease progression in MS patients prescribed with THC-based drugs and, hence, there are still no evidence of its neuroprotective effect in humans [379,417,418].…”

Section: Role Of Cannabinoids In Neurogenesis and Pathophysiologymentioning

confidence: 99%

Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology

et al. 2019

View full text Add to dashboard Cite

With the increase of life expectancy, neurodegenerative disorders are becoming not only a health but also a social burden worldwide. However, due to the multitude of pathophysiological disease states, current treatments fail to meet the desired outcomes. Therefore, there is a need for new therapeutic strategies focusing on more integrated, personalized and effective approaches. The prospect of using neural stem cells (NSC) as regenerative therapies is very promising, however several issues still need to be addressed. In particular, the potential actions of pharmacological agents used to modulate NSC activity are highly relevant. With the ongoing discussion of cannabinoid usage for medical purposes and reports drawing attention to the effects of cannabinoids on NSC regulation, there is an enormous, and yet, uncovered potential for cannabinoids as treatment options for several neurological disorders, specifically when combined with stem cell therapy. In this manuscript, we review in detail how cannabinoids act as potent regulators of NSC biology and their potential to modulate several neurogenic features in the context of pathophysiology.

show abstract

Experiencia clínica con los cannabinoides en la terapia de la espasticidad en la esclerosis múltiple

Abstract: THC/CBD appears to be a good alternative to standard treatment as it improves refractory spasticity in MS and has an acceptable toxicity profile.

Cited by 15 publications

References 12 publications

Nursing Students’ Knowledge and Attitudes Regarding Medical Marijuana: A Descriptive Cross-Sectional Study

Nursing Students’ Knowledge and Attitudes Regarding Medical Marijuana: A Descriptive Cross-Sectional Study

Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity

Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology

Contact Info

Product

Resources

About